CD95 (Fas/APO-1) is a member of the TNFR superfamily that induces apoptosis following cross-linking with its cognate ligand, CD95L (FasL/APO-1L) or agonist antibody. The human myeloma cell line, RPMI 8226, has limited sensitivity to CD95-mediated apoptosis, with a maximum of 65% of the population responding. To determine the source of the limited sensitivity to CD95-mediated apoptosis, we isolated multiple clones from the RPMI-8226 cell line by limiting dilution. Analysis of these clones demonstrated that sensitivity to CD95-mediated cell death directly correlated with CD95 expression. Clones with high levels of CD95 expression had greater than 90% cell death, whereas cells with low levels of expression had less than 10% cell death. In contrast, no correlative differences were identified for other members of the DISC complex, or for members of the anti-apoptotic Bcl-2 family. We further examined the sensitivity of the 8226 clones to various cytotoxic agents. Although modest clonal variability was demonstrated in response to the chemotherapeutic drugs, doxorubicin, etoposide (VP-16), and vincristine, there was no correlation between CD95 function and sensitivity to chemotherapeutic drugs. These results indicate that in this cell line, receptor expression is rate limiting in CD95-mediated apoptosis, whereas CD95 expression was not a determinant in drug-induced programmed cell death. Leukemia (2000) 14, 830-840.
Introduction
CD95 (Fas/APO-1) is a type I transmembrane receptor of the tumor necrosis factor receptor (TNFR)/nerve growth factor receptor (NGFR) superfamily. CD95 and other death receptors of this family are characterized by a cytoplasmic region known as the death domain that is required for initiation of apoptosis. 1 The death domain serves as a locus for recruitment and oligomerization of the death-inducing signal complex (DISC), and has been shown to be necessary and sufficient for caspase activation. Components of the DISC complex include the adapter protein FADD (MORT1), and the initiator caspase, procaspase-8 (FLICE/MACH/Mch5). [2] [3] [4] CD95 ligation by CD95L or anti-CD95 cross-linking antibody induces oligomerization of CD95 leading to DISC formation. This aggregation initiates the cleavage of caspase-8 to its active form. 5 Active caspase-8 propagates the cell death cascade by activating the downstream effector caspase, caspase-3 either by direct cleavage or through mitochondrial perturbation. 6 It has been hypothesized that mitochondrial-dependent activation of caspase-3 occurs when cytochrome c is released from the mitochondrial membrane to form a ternary complex with apoptotic protease activating factor-1 (Apaf-1) and caspase-9. 7, 8 formation results in a dATP-dependent cleavage and activation of caspase-9, which in turn leads to caspase-3 activation and apoptosis. [7] [8] [9] Several physiological mechanisms modulate apoptosis by inhibiting specific points in the caspase cascade. Overexpression of Fas-associated phosphatase 1 (FAP-1) has been shown to mediate resistance to CD95 in resting T cells and in pancreatic cancers. [10] [11] [12] The exact mechanism by which FAP-1 attenuates CD95 signaling has yet to be determined. However, the carboxy-terminal serine, leucine, and valine (SLV) of CD95 are known to be required for FAP-1 inhibition of CD95-induced apoptosis. 13 Zhou and colleagues 11 demonstrated that CD95 resistant, resting, peripheral T cells had significantly higher FAP-1 expression than cells sensitized to CD95-mediated apoptosis with IL-2 treatment. This report suggests that the resistance of quiescent T cells to CD95-mediated apoptosis may be at least partly due to regulation of FAP-1 expression.
Additional mechanisms contributing to the regulation of apoptotic signaling include the Bcl-2 family of proteins. Sixteen human Bcl-2 homologues have been identified and shown to both positively and negatively regulate programmed cell death.
14 Anti-apoptotic Bcl-2 family members include Bcl-2, Bcl-X L , Mcl-1, Bcl-w, and CED-9. These proteins have been shown to negatively regulate cell death initiated by ␥-irradiation, 15 certain cytotoxic drugs, 16 and CD95-mediated apoptosis. 6, 17 The mechanism of Bcl-2 family regulation of cell death has been shown to occur through heterodimerization of pro-and anti-apoptotic family members. Proapoptotic Bcl-2 family members, Bax, Bid, Bad, and Bik, are believed to promote cell death by associating with anti-apoptotic family members Bcl-X L and Bcl-2, thereby obstructing their anti-apoptotic function.
14 This model suggests that the ratio of anti-apoptotic to pro-apoptotic proteins is a key factor in determining sensitivity to programmed cell death-mediated by both physiological and chemotherapeutic factors.
Recently, evidence has accumulated to support the hypothesis that chemotherapeutic drugs utilize physiological mediators of apoptotic pathways. [18] [19] [20] [21] [22] Furthermore, several reports have implicated CD95-signaling as a mechanism of cell death mediated by certain cytotoxic drugs. 21, 23 Friesen et al 23 reported that doxorubicin and methotrexate induce CD95 and CD95L expression in human leukemia cell lines, and the cytotoxicity of these drugs could be attenuated with anti-CD95 F(abЈ) 2 fragments, suggesting a role for CD95/CD95L in drug-induced apoptosis. More recently, Fulda et al 21 reported a molecular ordering of doxorubicin-mediated apoptosis in neuroblastoma cells. In this study doxorubicin induced caspase-8 cleavage in cells ectopically expressing Bcl-2 or Bcl-X L . However, cytochrome c release and caspase-3 cleavage were blocked, demonstrating pre-mitochondrial activation of caspase-8. This molecular ordering demonstrates that chemotherapeutic agents may initiate PCD through a caspase-8 proximal event, implicating CD95/CD95L signaling. Although these results demonstrate that certain drugs utilize physiological cell death pathways, the point of convergence has yet to be defined. Furthermore, a direct contribution of the CD95/CD95L interaction to drug-induced cell death remains controversial.
We previously reported that the RPMI 8226 human multiple myeloma cell line expresses significant levels of CD95, however, challenges with CD95 agonist antibodies induced apoptosis in only 35-65% of cells. 22, 24 In this report, we examine the mechanism of the limited sensitivity of the 8226 cell line to CD95-mediated apoptosis. Clonal populations isolated by limiting dilution demonstrated significant heterogeneity in sensitivity to CD95-mediated apoptosis. Moreover, CD95 cell surface expression was demonstrated to directly correlate with response to cross-linking with agonist antibody in the 8226 clones. Therefore, using an established isogenic cell system, isolated without selective pressure, we demonstrated that CD95-expression was the major determinant for Fas-induced programmed cell death. Additionally, utilizing the unique nature of this CD95-determinant cell system, we were able to examine the correlation between clonal variability in CD95 expression and function, and cellular response to chemotherapeutic agents.
Materials and methods

Cell culture and isolation of RPMI 8226 clones
The human multiple myeloma cell line 8226 was originally acquired from ATCC (Rockville, MD, USA), and maintained in RPMI 1640 (Mediatech-Cellgro, Seattle, WA, USA), supplemented with 5% heat inactivated fetal bovine serum (Omega Scientific, Tarzana CA, USA), 100 M L-glutamine and 100 U/ml penicillin/streptomycin (Gibco, Grand Island, NY, USA). Cells were maintained at 37°C in 5% carbon dioxide. RPMI 8226 clones were isolated by limiting dilution. Cells were maintained at 37°C for 14 days and examined for colony formation. Clonal populations were expanded and established as stable cell lines in culture for at least eight passages. Clonality of the established cell lines was determined by Poisson's probability distribution.
Apoptosis assays
All assays were performed on cells in logarithmic growth. Cytotoxicity was determined by the ability of viable cells to metabolize the tetrazolium salt, MTT to formazan (Sigma, St Louis, MO, USA). Cells were incubated with serial dilutions of doxorubicin, etoposide, or vincristine (all from Sigma) for 96 h, at which time 50 l of MTT dye (2 mg/ml in PBS, Sigma) was added and incubated for an additional 4 h. Plates were centrifuged and the supernatant was replaced with 100 l of DMSO to solubilize the formazan complex. Formazan optical density was determined with a Dynex II ELISA plate reader at 540 nm (Dynex Technologies, Chantilly, VA, USA). For analysis of CD95-mediated cell death, cells were plated at 4.5 × 10 5 /ml in complete media and incubated with crosslinking antibody (CH-11, MBL International, Watertown, MA, USA) or CD95L ligand (Alexis, San Diego, CA, USA) for 16-18 h. Viability was determined by MTT dye reduction. All data represent the mean of three independent assays with replicates of four, presented as percent of control.
Apoptotic cell death was determined by measuring Leukemia Annexin-V staining by flow cytometry (FCM).
22 Cells (2.5 × 10 5 ) were incubated with 400 ng/ml CH-11 for 16 h, collected, washed once with PBS, then resuspended in Annexin-V buffer (Bio Vision Research Products, Palo Alto, CA, USA). The samples were then incubated with 0.5 l FITC conjugated Annexin-V for 5 min in the dark at room temperature. Phosphatidylserine membrane flipping was then analyzed with Cell Quest software (Becton-Dickinson, Mountain View, CA, USA). Apoptosis is reported as percent specific apoptosis ([experimental apoptosis − spontaneous apoptosis/ 100 − spontaneous apoptosis] × 100).
RNA isolation and RNase protection assay
Total RNA was isolated from 5.0 × 10 6 cells by TRIzol reagent (Gibco BRL). RNase protection assays (RPA) were carried out using the Pharmingen Riboquant hAPO-3c (CD95 and DISC components) and hAPO-2 (Bcl-2 family members) multi-probe templates according to the manufacturer's protocol (Pharmingen, San Diego, CA, USA). Briefly, the multi-probe template was synthesized by in vitro transcription with incorporation of [ 32 P]-␣ UTP and purified on a G50 sephadex column (5-Prime to 3-Prime, Boulder, CO, USA). Specific activity was quantitated in a Beckman LS 6500 scintillation counter (Beckman, Schaumburg, IL, USA). Purified probe (0.8-1.5 × 10 6 c.p.m./l) was hybridized with 20 g of total RNA for 16 h followed by RNase digestion at 37°C for 1 h. Protected RNA fragments were separated on a 5% polyacrylamide, denaturing gel and quantitated with Image Quant software (Molecular Dynamics, Sunnyvale, CA, USA).
Flow cytometric analysis of CD95 expression
CD95 surface expression was determined using FCM. Cells were washed twice with phosphate buffered saline and blocked with 50 l of 0.2 mg/ml reagent grade mouse IgG molecules (Sigma) for 15 min at room temperature. Samples were then incubated with FITC-conjugated anti-CD95 (UB2) (MBL International) or anti-IgG 1 isotype control (Caltag Laboratories, Burlingame, CA, USA) for 30 min at room temperature. Fluorescence intensity was analyzed by flow cytometry using Cell Quest software (Becton-Dickinson). Data represent the median fluorescence (UB2) above isotype control (UB2 median fluorescence-isotype fluorescence), and is representative of at least four experiments.
Caspase activation
Caspase-8 and caspase-3 activation was determined by Western blot analysis. Cells were treated for the indicated time with 400 ng/ml CH-11 or 5 M doxorubicin, washed twice with ice cold phosphate buffered saline, then incubated for 30 min at 4°C in lysis buffer (30 mM Hepes, 10 mM NaCl 2 , 5 mM MgCl 2 , 25 mM NaF, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 2 mM Na-orthovanadate, 25 g/ml leupeptin, 10 g/ml aprotinin, 2 mM PMSF, and 10 g/ml soy bean trypsin inhibitor). Protein lysates were quantitated with BioRad reagent (BioRad, Hercules, CA, USA) and 75-100 g of cellular lysates were separated on 12.5-15% polyacrylamide gels and transferred to PVDF membrane. Caspase activation was detected with anti-caspase-8 or caspase-3 polyclonal antiserum (both generously provided by Dr H-G Wang, H Lee Moffitt Cancer The human multiple myeloma cell line RPMI 8226 has limited sensitivity to agonist antibody-mediated apoptosis. RPMI 8226 cellular sensitivity to CH-11 was compared to the CD95 sensitive Jurkat cell line. Response was assayed by the ability of viable cells to metabolize the tetrazolium salt MTT to formazan (a). Viability was presented as a percent of control survival; each data point represents the mean of three experiments. RPMI 8226 (᭹) and Jurkat ()). Annexin V staining was used to confirm the apoptotic nature of the death (b). Apoptosis is presented as percent specific apoptosis: ((experimental apoptosis − spontaneous apoptosis)/ (100 − spontaneous apoptosis)) × 100.
Center). All membranes were assayed for equal loading using antibodies to the house-keeping protein ␤-actin (Sigma) and visualized with Lumi-Light chemiluminescence (Boehringer Mannheim, Indianapolis, IN, USA).
Results
The human myeloma cell line RPMI 8226 has limited sensitivity to CD95-mediated apoptosis
Previously published studies have demonstrated a broad range of CD95 expression and sensitivity to CD95-mediated apoptosis, in both multiple myeloma cell lines and patient specimens. 22, 25, 26 Moreover, we have demonstrated that although expressing significant CD95 antigen, the RPMI 8226 cell line is only partially responsive to CD95-induced cell death. The response of RPMI 8226 to increasing levels of CD95 agonist antibody, CH-11, is limited with a maximum of 65% of the cells undergoing apoptosis. Initial response is obtained with as little as 50 ng/ml of antibody. Incubation with higher doses ranging from 200 to 800 ng/ml CH-11 results in only minimal changes in cell survival ( Figure 1a ) and response and is not appreciably enhanced by extended antibody exposure (data not shown). This is in contrast to other cell lines, including the Jurkat T cell line, that undergo nearly complete apoptosis (Ͼ95%) when cross-linked with CD95 agonist antibody ( Figure 1a) . Furthermore, flow cytometric analysis of the 8226 cell line following cross-linking with 400 ng/ml CH-11 revealed an Annexin V positive and an Annexin V negative peak, suggesting the existence of CD95-sensitive and resistant populations (Figure 1b) . In contrast, when Jurkat cells are treated under the same conditions virtually all cells undergo apoptosis ( Figure 1b) .
To determine if the limited sensitivity of the 8226 cell line to CD95-mediated cell death was an inherent characteristic of the cells or due to epigenetic factors, we isolated clonal populations by limiting dilution. Eleven clones were initially examined for CD95 sensitivity, and three representative clones were chosen for further characterization. The clonal cell lines 8226/S L (low sensitivity), 8226/S I (intermediate sensitivity), and 8226/S H (high sensitivity) were incubated with increasing concentrations of CH-11 for 16 h and assayed by MTT dye reduction ( Figure 2 ). The clonal cell line 8226/S L shows almost complete resistance with 95% survival, the 8226/S I shows moderate sensitivity, and the 8226/S H is exquisitely sensitive, with an 8% survival at the highest dose of CH-11 ( Table 1 ). The variable sensitivity of the clones to CD95-mediated apoptosis was confirmed by Annexin-V analysis (data not shown).
CD95 expression determines sensitivity to CD95-mediated apoptosis
To analyze the correlation between CD95 expression and sensitivity, CD95 expression was measured in the 8226 clonal cell lines. As shown in Figure 3a , CD95 surface expression was highly variable between the clones. The 8226/S H clone, which demonstrated the greatest sensitivity to CD95-mediated apoptosis, expressed the highest levels of CD95 on the cell surface. Significantly less surface expression was detected on the 8226/S I and almost no expression was detected on the 8226/S L clone. To determine if CD95 cell surface expression correlated with RNA expression, CD95 RNA was analyzed using RNase protection assay (RPA) (Figure 3b ). RPA analysis showed a high degree of variability between the three clones and the parental cell line for CD95 RNA expression. Clone 8226/S L , had significantly lower expression compared to the parental cell line (0.52-fold (P = 0.0487)), clone 8226/S H , had significantly higher expression of CD95 than the parental cell line (3.03-fold (P = 0.0419)), and clone 8226/S I had slightly higher CD95 RNA expression than the parental cell line (1.59-fold (P = 0.0490)) ( Table 1) . Comparison of CD95 RNA expression between the clonal populations determined that expression of this death receptor was significantly different (8226/S H vs 8226/S L (P = 0.0098), 8226/S H vs 8226/S I (P = 0.0475), and 8226/S I vs 8226/S L (P = 0.0036)). As illustrated in Figure 3a and b, CD95 RNA expression correlated directly with cell surface expression, suggesting that the different levels of CD95 expression is transcriptionally regulated. In these studies, we have isolated three clones, 8226/S L , a CD95 resistant clone with almost no expression of CD95, 8226/S H , a highly CD95 sensitive clone with a high degree of CD95 expression, and 8226/S I , a moderately sensitive clone with only slightly higher expression than the parental cell line. To determine the relevance of the relationship between CD95 expression and sensitivity we utilized two methods of statistical analysis. As shown in Figure 3c , CD95 expression has a positive and linear relationship with physiological function; as the level of expression increased the greater the number of cells underwent apoptosis (Pearson's correlation coefficient; 0.99806 (P = 0.0019). Secondly, regression analysis of the independent variables CD95 expression and log-dose CH-11 demonstrated a highly statistically significant correlation with the percent survival (P р 0.0001 and P = 0.01, respectively). These statistical analyses demonstrate that clonal CD95 expression directly parallels a receptor-dependent variability in sensitivity to CD95-mediated programmed cell death.
Leukemia
Expression of FADD/MORT1 and caspase-8/FLICE does not vary between the 8226 clones
Apoptotic signaling from the CD95 antigen requires oligomerization and recruitment of the DISC components FADD/MORT1 and caspase-8/FLICE/MACH1. 2,4,27 As we have shown, CD95 is expressed heterogeneously in the 8226 clones, and this expression directly correlates with sensitivity of the clones to CD95-mediated cell death. To determine if heterogeneity in other CD95 death promoting factors also contributed to clonal sensitivity for CD95-mediated cell death, we examined the RNA expression of the DISC components, caspase-8 and FADD (Figure 4) . We found that caspase-8 expression did not vary to a significant degree between either the clones and the parental cell line, or between the clonal populations. FADD expression, although exhibiting significant variation between the clones and the parental cell line, showed no significant difference between the clonal populations (data not shown). These results indicate that caspase-8 and FADD expression is unlikely to be involved in the variable sensitivity of the 8226 clones to CD95-mediated apoptosis.
CD95 mediated caspase activation correlates with CD95 expression and sensitivity
CD95-mediated apoptosis involves oligomerization and cleavage of the initiator caspase, procaspase-8. 28 Caspase-8 activation has been shown to elicit a mitochondrial-dependent or independent activation of caspase-3 and subsequent morphological changes associated with apoptosis. 6 To determine if effectors of the proteolytic cascade contributed to the variable sensitivity of the 8226 clones to CD95-mediated apoptosis, caspase-3 activation was examined following ligation with agonist antibody. The kinetics of caspase activation was examined by observing the accumulation of caspase-3 cleavage products following treatment with 400 ng/ml of anti- CD95 expression directly correlates with sensitivity to CD95-mediated apoptosis. Clonal cell lines were examined for CD95 surface expression and mRNA expression. Clonal CD95 surface expression was determined by direct immunofluorescent staining using flow cytometric analysis (a). The dark peak represents the fluorescence of the isotype (IgG 1 -FITC CD95 agonist antibody ( Figure 5 ). As shown, the resistant clone, 8226/S L demonstrated minimal cleavage (activation) of caspase-3 from 0 to 16 h, consistant with its resistance to CD95-mediated apoptosis. In contrast, cleavage products were detectable as early as 2 h in the hypersensitive clone, 8226/S H and the moderately sensitive clone, 8226/S I . Furthermore, in correlation with the higher death response, the overall level of caspase cleavage product was much greater in the hypersensitive clone. These data demonstrate that CD95 surface expression directly contributes to the degree of caspase activation following treatment with CD95 agonist antibody.
Expression of anti-apoptotic Bcl-2 family members and FAP-1 are not determinants of clonal sensitivity to CD95-mediated apoptosis
The anti-apoptotic members of the Bcl-2 family have been shown to attenuate CD95-mediated death signaling in many cell types, including multiple myeloma. 6, 17, 29 Therefore, we wanted to determine if RNA expression of the anti-apoptotic Bcl-2 family members, Bcl-2, Bcl-X L , and Mcl-1 varied between the 8226 clones and the parental cell line and between the clonal populations. As illustrated in Figure 6a , statistically significant heterogeneity is observed in Bcl-X L and Bcl-2 when comparing the clones to the parental cell population. Furthermore, comparison of these anti-apoptotic fac- CD95 sensitivity and expression correlate with caspase activation. The kinetics of caspase activation following CD95 cross-linking was determined by Western blot analysis. Caspase-3 cleavage was measured at the indicated time points following stimulation with 400 ng/ml CH-11. Procaspase-3 is a 32 kDa protein (p32) activated by cleavage into a large (p20/17) catalytic and a small regulatory subunit (p10). Activation of procaspase-3 is detected using a polyclonal antibody that recognizes both the procaspase and the large cleavage products (p20/17) following treatment with CH-11. Equal loading was determined with antiserum to the house-keeping protein ␤-actin. Fas-associated phosphatase-1 (FAP-1) has also been identified as a potential negative regulatory factor in CD95-mediated cell death. 11 The mechanism of regulation has yet to be resolved, however, it has been shown that increased FAP-1 expression may contribute to resistance to CD95-mediated apoptosis in resting T cells. 11 We therefore examined FAP-1 RNA in the 8226 clones by RPA (Figure 6d ). As illustrated in Figure 6d , FAP-1 RNA expression was elevated in all clones as compared to the parental cell line. However, comparison of FAP-1 RNA expression between the clonal populations revealed no significant differences, suggesting that FAP-1 RNA expression does not contribute to clonal sensitivity to CD95-mediated apoptosis.
CD95 expression does not correlate with sensitivity to cytotoxic drugs
Several studies have shown an induction of CD95 expression by some chemotherapeutic drugs, suggesting that CD95 may contribute to the drug cytotoxicity. 21, 23 If CD95 contributed to drug-mediated apoptosis, then we would predict that the 8226 clone with decreased CD95 expression would be relatively drug resistant, while those with elevated expression would be relatively hypersensitive to cytotoxic drugs. We therefore examined the sensitivity of the 8226 clones to a panel of cytotoxic agents. Figure 7 demonstrates no significant correlation of CD95 expression and function with sensitivity to the anticancer drugs, doxorubicin, etoposide, and vincristine as determined by MTT dye reduction (Pearson correlation coefficient: −0.55216 (P = 0.448), −0.48051 (P = 0.520), −0.22302 (P = 0.777)). The IC 50 for each clone and drug are summarized in Table 1 . These data suggest that altered CD95 expression does not predict an altered sensitivity to these cytotoxic drugs. Examination of Bcl-2, Bcl-X L , and Mcl-1 expression and drug cytotoxicity demonstrated no statistically significant relationship (data not shown). Of the expression variables examined, Leukemia only FADD and FAP-1 showed a significant correlation with drug sensitivity, and this relationship was observed only in response to etoposide (data not shown). A positive correlation was observed between FADD RNA expression and etoposide sensitivity; increased FADD expression coincided with increased sensitivity to etoposide-mediated cell death. Interestingly, the expression of FAP-1, a negative regulator of CD95-mediated apoptosis, also demonstrated a positive correlation with sensitivity to etoposide.
CD95 expression and sensitivity do not correlate with chemotherapeutic drug-mediated caspase activation
We have shown that 8226 clones with differential CD95 expression are equally sensitive to drug-mediated apoptosis (Figure 7) , suggesting that drugs can eliminate cells independently of CD95. We next wanted to investigate the kinetics of drug-mediated caspase cleavage in the CD95 variable 8226 clones. To analyze initiation of doxorubicin mediated caspase activation we examined the rates of caspase-8 and caspase-3 cleavage. We found that in the parental cell line and all clones examined, doxorubicin initiates cleavage of both caspase-8 and caspase-3 with similar kinetics (Figure 8) . In both the CD95-resistant (8226/S L ) and the CD95-hypersensitive (8226/S H ) clones, doxorubicin induced turnover of the proenzyme and accumulation of active caspase-8 and caspase-3 cleavage products by 6 h, with nearly complete turnover of the respective procaspase by 16 h. The identical kinetics of caspase activation between the 8226 clones further supports the hypothesis that CD95 expression does not contribute to drug-induced caspase activation.
Previously, we demonstrated that extracellular inhibition of CD95 signaling had no effect on doxorubicin-mediated caspase-3 cleavage in a CD95-selected cell line. 22 To further investigate the role of CD95 in drug-mediated caspase activation we examined the cellular response to doxorubicin following treatment with inhibitors of CD95-mediated apoptosis in the unselected 8226 clones, reducing the potential influence of selection specific alterations in apoptotic signaling. In Figure 9a , we show that both ZB4, an antibody that blocks extracellular activation of CD95 signaling events, and zVADfmk, an irreversible broad spectrum caspase inhibitor are both potent inhibitors of CD95-mediated caspase activation. However, parallel experiments with doxorubicin demonstrated that only zVAD-fmk was able to attenuate caspase-8 and caspase-3 cleavage (Figure 9b ). The inability of the CD95 specific inhibitor to alter the response to doxorubicin suggests that this cytotoxic drug can initiate caspase activation independently of CD95-specific extracellular signaling events.
Discussion
The human multiple myeloma cell line 8226 is only partially responsive to CD95-mediated apoptosis. In this study we demonstrate that the limited sensitivity of this cell line directly CD95 activity does not correlate with doxorubicin-mediated cleavage of caspase-8 and caspase-3. The kinetics of caspase-8 and caspase-3 activation following treatment with 5 M doxorubicin was determined by Western blot analysis. Protein was isolated at the indicated time points and analyzed for turnover of the proenzyme and accumulation of the cleavage products. Equal loading was determined with antiserum to the house-keeping protein ␤-actin.
correlates with heterogeneous CD95 expression and function. Three representative clonal populations isolated from the RPMI 8226 cell line demonstrated significantly different levels of CD95 expression. The CD95 antigen high expressing clone (8226/S H ) was exquisitely sensitive to CD95-mediated apoptosis, while the clones expressing lower levels (8226/S I ) or almost no CD95 (8226/S L ) were relatively resistant to crosslinking antibody. Furthermore, we show that CD95 expression and sensitivity directly correlate with caspase-3 activation. These results demonstrate that CD95 expression is the major determinant for cellular sensitivity to CD95-mediated apoptosis in some cell types.
Programmed cell death mediated by CD95 is regulated by several receptor-associated factors including, caspase-8, FADD, and FAP-1. In this report, we demonstrate that no significant correlation exists between CD95-mediated cell death and expression of these receptor-associated factors. However, we cannot exclude the existence of other factors that may be involved in CD95 signaling events. For example, the newly identified CD95 proximal CED-4 homologue, FLICE-associated huge protein (FLASH) has been shown to be necessary for CD95 and TNFR-mediated apoptosis in CD95-expressing 293 cells. 30 Imai and colleagues 30 demonstrated that FLASH associates with both caspase-8/FLICE and FADD and coimmunoprecipitates with CD95 following receptor cross-linking. Identification of this new component of the DISC complex demonstrates the complexity of death receptor signaling, and that other CD95 associated factors not addressed in this report may also affect the sensitivity of these clones to CD95-mediated apoptosis.
Physiological death mediated by death receptors has been demonstrated to be regulated by factors distal to the DISC complex. In some cell types, CD95-mediated apoptosis is vulnerable to the anti-apoptotic mechanisms of the Bcl-2 family. 6, 15 For example, the IL-6 dependent multiple myeloma cell line U266 has significant CD95 expression, but is completely resistant to cross-linking-mediated apoptosis. The resistant nature of U266 cells is at least partially the result of high constitutive expression of Bcl-X L . 17 Catlett-Falcone and colleagues 17 demonstrated that reduction of Bcl-X L expression by inhibiting STAT3 reversed the CD95-resistant phenotype in this cell line. We therefore examined the possibility that clonal variability in Bcl-2 family expression may contribute to the altered response to CD95 agonist antibody. Analysis of the RPMI 8226 clones for Bcl-2, Bcl-X L , and Mcl-1 RNA expression demonstrated minor variation in clonal expression Leukemia of the Bcl-2 family members. However, expression levels of these factors did not significantly correlate with susceptibility to CD95-mediated apoptosis. These data support the hypothesis that in the 8226 cell line, CD95 expression is the predominant factor contributing to CD95 sensitivity.
In this report, we have shown that expression of several anti-apoptotic factors did not correlate with the sensitivity of 8226 clones to CD95-mediated apoptosis. The unique nature of this isogenic, unselected cell line system enabled us to further evaluate the role of CD95 in drug-induced programmed cell death. The requirement for CD95 and its cognate ligand in drug cytotoxicity is controversial. Reports have suggested that certain cytotoxic drugs utilize CD95/CD95L interactions to mediate death. 23 This work is exemplified in early works by Friesen et al, 23 showing that in Jurkat and CEM leukemia cell lines, doxorubicin-mediated apoptosis can be inhibited by blocking F(abЈ) 2 anti-APO-1 antibody fragments. In their report, Freisen et al also show that CD95 and CD95L RNA expression increase in response to doxorubicin treatment. The authors suggest that increased abundance of CD95 and CD95L is paramount to doxorubicin initiated cell death, and that cellular drug response may be initiated by CD95/CD95L interactions. Other reports demonstrate that the cytotoxic response to drugs occurs independently of CD95L. 31, 32 In keratinocytes, Aragane et al demonstrated a plasma membrane clustering of CD95 in responses to UVirradiation, initiating auto-oligomerization of the receptor and propagation of the apoptotic signal. 31, 32 Yet other reports demonstrate that although drugs utilize similar downstream effectors of apoptosis, such as caspases, neither CD95 nor CD95L are essential to the cytotoxic drug response. 18, 23, 33, 34 Previously, we have shown that selection for resistance to doxorubicin and mitoxantrone co-selects for CD95 resistance. However, selection of a CD95 resistant 8226 myeloma cell line does not alter susceptibility to a panel of anticancer drugs, indicating that drugs and CD95 activate caspases by independent mechanisms. 22, 24 In addition, Villunger et al 35 provide evidence that doxorubicin, cisplatin, and fludarabine treatment augmented CD95L expression, however, drugmediated cell death was not inhibited by CD95-specific antibodies. Taken together, these results demonstrate that in some cell models the convergence of drug and physiological cell death may take place downstream of the CD95 receptor.
Using the 8226 clones with varying sensitivity to CD95-mediated apoptosis, we were able to examine the question of whether CD95 expression contributes to the cytotoxicity of CH-11 mediated caspase activation is inhibited both by anti-CD95 blocking antibodies and caspase tetrapeptide inhibitors, but only caspase-specific agents block doxorubicin-induced caspase activation. In the hypersensitive clone, 8226/S H CH-11 induced caspase-8 and caspase-3 cleavage was determined by Western blot for cells untreated or pretreated for 2 h with the CD95 blocking antibody ZB4 (1 g/ml) or the caspase inhibitor zVAD-fmk (50 M) (a). Cells were incubated with 400 ng/ml CH-11 for 16 h. Doxorubicin (5 M)-mediated caspase cleavage was determined under the same conditions (b). Equal loading was determined with antiserum to the house-keeping protein ␤-actin. chemotherapeutic drugs. One would predict that if CD95 signaling events were required for drug cytotoxicity, then differential CD95 expression would correlate with differential drug sensitivity. In this study, we demonstrate that cellular sensitivity to doxorubicin, etoposide, and vincristine are independent of CD95 expression. Activation of the caspase cascade in response to doxorubicin was also similar between clonal populations, and independent of CD95 expression. Furthermore, the rate of zymogen turnover in response to drugs did not correlate with CD95-mediated caspase cleavage. Taken together these results advance the hypothesis that CD95 does not play an essential role in drug-mediated apoptosis in the RPMI 8226 cell line. Moreover, the absence of a correlation between CD95 function and sensitivity, and cytotoxic drug-mediated programmed cell death imply that factors other than the CD95 antigen may be targeted to initiate drug-mediated apoptosis. In a recent report, Sun et al 36 support this notion by showing that etoposide induces a caspase and Bid-independent release of cytochrome c from the mitochondria. In contrast, CD95-induced cytochrome c release was dependent on caspase activation. These results imply that cytochrome c and/or other factors associated with the mitochondria are important for anticancer drug-mediated cell death in some cell types. The 8226 clones described here may provide an ideal model system for investigating CD95-independent mechanisms of drug-mediated programmed cell death.
Finally, in isolating the RPMI 8226 clones we have demon-strated an unselected heterogeneity within the 8226 cell population. We identified significant variability in both CD95 sensitivity and expression in the 8226 clones. Moreover, we showed that the variability in CD95 sensitivity directly correlated with cellular sensitivity to CD95-induced apoptosis.
Other reports have examined the correlation between CD95 expression and sensitivity to CD95-mediated apoptosis. 25, 26, 37 Shima and colleagues 38 examined the relationship between CD95 expression and sensitivity to death receptor-mediated apoptosis in several multiple myeloma cell lines and patient specimens. This report demonstrated that CD95 expression correlates to some degree with sensitivity to CD95 death signaling, however, this trend was not consistent over all the cell lines investigated. 38 The results of this investigation were limited by the fact that the role of CD95 expression in death receptor-mediated cell death was examined across multiple hematopoietic cell lines and patient specimens. In each case tissue specific factors other than CD95 expression may regulate cellular sensitivity to CD95-mediated apoptosis including, overexpression of Bcl-2 family members, 17, 39, 40 or function ablating mutations in CD95L and CD95, as found in gld and lpr mice. 41, 42 More recently, Tillman et al 43 examined 10 colon carcinoma cell lines, four CD95 sensitive and six CD95 resistant. In these colon carcinoma cell lines CD95 expression correlated with sensitivity to CD95-mediated apoptosis. In this report, we characterized an isogenic cell line by isolating several clonal populations of cells without selective pressure. With this isogenic system we were able to demonstrate that CD95 expression was the primary determinant for CD95-mediated apoptosis, but that no correlation was observed between CD95 expression and cytotoxic drug-induced programmed cell death.
